[Federal Register Volume 71, Number 236 (Friday, December 8, 2006)]
[Rules and Regulations]
[Page 71038]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-20929]



[[Page 71038]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520


Oral Dosage Form New Animal Drugs; Lincomycin and Spectinomycin 
Powder

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Final rule.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of an abbreviated new animal drug 
application (ANADA) filed by Agri Laboratories, Ltd. The ANADA provides 
for the oral use of lincomycin and spectinomycin soluble powder to 
create a solution administered in the drinking water of chickens as an 
aid in the control of airsacculitis.

DATES:  This rule is effective December 8, 2006.

FOR FURTHER INFORMATION CONTACT:  John K. Harshman, Center for 
Veterinary Medicine (HFV-104), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-827-0169, e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: Agri Laboratories, Ltd., P.O. Box 3103, St. 
Joseph, MO 64503, filed ANADA 200-407 that provides for use of 
Lincomycin-Spectinomycin (lincomycin hydrochloride and spectinomycin 
dihydrochloride pentahydrate) Water Soluble Powder to create a solution 
administered in the drinking water of chickens as an aid in the control 
of airsacculitis caused by either Mycoplasma synoviae or M. 
gallisepticum susceptible to lincomycin-spectinomycin and complicated 
chronic respiratory disease (air sac infection) caused by Escherichia 
coli and M. gallisepticum susceptible to lincomycin-spectinomycin. Agri 
Laboratories, Ltd.'s Lincomycin-Spectinomycin Water Soluble Powder is 
approved as a generic copy of L-S 50 Water Soluble Powder, sponsored by 
Pharmacia & Upjohn Co., a Division of Pfizer, Inc., under NADA 046-109. 
The ANADA is approved as of November 9, 2006, and the regulations are 
amended in 21 CFR 520.1265 to reflect the approval. The basis of 
approval is discussed in the freedom of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    FDA has determined under 21 CFR 25.33(a)(1) that this action is of 
a type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor an environmental impact statement is required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 520

    Animal drugs.

0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 520 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.

0
2. In Sec.  520.1265, revise the section heading and paragraph (b)(2) 
to read as follows:


Sec.  520.1265  Lincomycin and spectinomycin powder.

* * * * *
    (b) * * *
    (2) Nos. 057561, 059130, and 061623 for use of product described in 
paragraph (a)(2) of this section.
* * * * *

    Dated: November 28, 2006.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. E6-20929 Filed 12-7-06; 8:45 am]
BILLING CODE 4160-01-S